AC
ALNY icon

Avestar Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Avestar Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15
Closed -$1K – 843
2019
Q1 		$1K Hold
15
– – ﹤0.01% 691
2018
Q4 		$1K Buy
+15
New +$1.15K ﹤0.01% 678
2018
Q1 		– Hold
0
– – – 678

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Avestar Capital's ALNY Position: Q2 2019 in Review

Avestar Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2019, closing a stake of 15 shares — an estimated $1K sold.

Avestar Capital first reported a position in ALNY in Q4 2018 and held it in 2 quarters. The position peaked at $1K in Q1 2019. 290 funds tracked by Wall St. Rank hold ALNY as of Q2 2019.

  • Avestar Capital reported no remaining Alnylam Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Avestar Capital sold 15 Alnylam Pharmaceuticals shares in Q2 2019, an estimated $1K.
  • Avestar Capital first reported a position in Alnylam Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Avestar Capital's Alnylam Pharmaceuticals position peaked at $1K in Q1 2019.
  • 290 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2019.

Based on Avestar Capital's 13F filing for Q2 2019, filed 6 Aug 2019.